Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance) is a research paper published in Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 15 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Ipsen
Grant: U10CA180821
NCI NIH HHS
Grant: P30 CA008748
Ipsen
Grant: UG1CA189823
NCI NIH HHS
Grant: U10 CA180882
NCI NIH HHS
Grant: UG1 CA233373
NCI NIH HHS
Grant: UG1 CA233290
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 3U10CA180821-02S2
Alliance for Clinical Trials in Oncology Operations Center
National Institutes of Health
Grant: 5UG1CA189823-04
Alliance NCORP Research Base
National Institutes of Health
Grant: 5U10CA180882-02
Statistics and Data Center for the Alliance for Clinical Trials in Oncology
FWCI
1.43
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals